Globus Medical, a leading musculoskeletal solutions company, has announced its acquisition of Nevro Corp, a global medical ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million ...

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share.

Globus Medical and Nevro Preliminary Full-Year 2024 Revenue Outlook: On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year ...

Globus Medical expects the Nevro acquisition to be accretive to its earnings in the second year of operation. Globus Medical expects to report full financial results for 2024 and provide its updated ...

Buying $100 In GMED: If an investor had bought $100 of GMED stock 10 years ago, it would be worth $356.36 today based on a price of $86.88 for GMED at the time of writing.

Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an all-cash ...